US-based molecular diagnostics firm Biocept has commercially launched its new liquid biopsy progesterone receptor (PR) test to detect and monitor select biomarker in breast cancer patients.
Based on the Target Selector platform, the new assay is designed to detect PR expression in circulating tumour cells (CTCs) and is performed on CTCs using fluorescently labelled antibodies.
The PR expression test complements the firm’s existing ER and HER2 assays developed for breast cancer biomarker analysis.
Biocept president and CEO Michael Nall said: "We now have 14 commercially available liquid biopsy assays as we execute on our initiative to expand our product menu of non-invasive, cost-effective biomarker tests.
“Our goal is to offer tests to detect and track all clinically actionable biomarkers listed in the NCCN Guidelines for solid tumours, which we believe is a compelling value proposition for Biocept in the liquid biopsy market."
The National Comprehensive Cancer Network (NCCN) is a non-profit organisation formed as a collaboration between 27 cancer centres to deliver improved cancer care.
The NCCN Clinical Practice Guidelines comprise evidence-based, consensus-driven management to provide preventive, diagnostic, treatment and supportive services to patients.
Biocept portfolio includes commercialised assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.
The firm’s Target Selector liquid biopsy technology platform captures and analyses tumour-associated molecular markers in both CTCs and in circulating tumour DNA (ctDNA).
The ability of the platform to detect cancer mutations and alterations is validated through numerous tests for providing optimal disease information and therapeutic options.